High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Dividend funds pulled in $24.1 billion in the first quarter of 2026, their strongest opening quarter in four years, and a lot of that cash went looking for a boring place to hide from AI-hype exhaustion. The iShares Core High Dividend ETF (NYSEARCA:HDV) is one of them. HDV holds 75 positions, charges 0.08%, and yields ... A 2.86% Yield, 0.08% Fee, and 75 Stocks: Is HDV the Anti-Hype ETF?
Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.
Abivax (ABVX) shares have rebounded to pre-Phase 3 maintenance data levels as investor concerns over
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
AMAT, MA, ABBV, VATE and BOF headline new research reports highlighting AI, payments, healthcare and microcap growth opportunities.
Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) pays a quarterly distribution from roughly 100 quality-screened U.S. dividend stocks. The fund holds $71.6 billion in assets at an expense ratio of just 0.06%, and it tracks the Dow Jones U.S. Dividend 100 Index, which requires 10 consecutive years of dividend payments and screens on cash flow to ... Six Dividend Aristocrats Keeping SCHD’s Income Stream Bulletproof This Year
U.S. lawmakers have opened a bipartisan national security investigation into AbbVie (NYSE:ABBV) and other pharmaceutical companies. The inquiry focuses on AbbVie’s clinical trials in China, including work at facilities reportedly linked to the Chinese military and sites in the Xinjiang region. Congress has requested detailed information on research practices, data protection, and site vetting, with responses due by mid-July. AbbVie is a large U.S. pharmaceutical company with a portfolio...
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.
The average Social Security retirement check reached $2,081 per month as of April 2026, according to the Social Security Administration’s monthly statistical data. That figure carries the 2.8% cost-of-living adjustment that took effect in January 2026. Replacing roughly that amount with dividend income is a math problem before it is an investing problem, and the ... Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It.
WST has surged nearly 33% YTD as strong earnings, GLP-1 demand and biologics growth fuel momentum that could extend through 2026.
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State
Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S
Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...
JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.
Dividend investors entering July 2026 have a rare setup: Three of the market’s most reliable income stocks all delivered beat-and-raise first-quarter reports, all hiked their payouts in the past 12 months and all three are riding meaningful momentum into the back half of the year. The thesis is simple. When defensive cash-flow machines start outperforming, ... 3 Dividend Stocks to Buy Hand Over Fist in July
GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock. This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that […]
AbbVie Inc. (NYSE:ABBV) is one of the best dividend aristocrat stocks to buy now. On June 19, AbbVie Inc. (NYSE:ABBV) delivered topline Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress. The results from the Phase 3 CLL14 trial affirm venetoclax’s enduring safety and efficacy in untreated chronic […]
JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.
The iShares MSCI USA Momentum Factor ETF (NYSEARCA:MTUM) has run hard this year, climbing 30% year to date and 38% over the past 12 months to roughly $326. Headline numbers, though, mask a violent rotation inside MTUM’s portfolio. The AI/cloud mega-caps that powered the momentum trade through 2025 have stumbled, while one AI-memory name has ... MTUM Investors: Watch Micron’s Weight at the November Reconstitution
Galderma shares fell after the Swiss skincare specialist failed to obtain approval from the U.S. Food and Drug Administration for its latest product to rival AbbVie’s Botox for the second time. Shares in Galderma were down 5.6% in European morning trading Wednesday, leaving the stock up 7% since the start of the year. The company said it received a complete response letter from the FDA declining its application for the product—marketed in some countries as Relfydess and also known as relabotulinumtoxinA—with comments related to observations during an inspection of the company’s manufacturing site and its analytical method optimization.
AbbVie knows how to plan ahead.
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.9%
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
A bipartisan House committee wants details on hundreds of clinical studies conducted at Chinese military facilities and in Xinjiang
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
